Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States. The aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.

NCT Number	NCT06899204
Lead Sponsor	Pfizer
Conditions	Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
Enrollment	150 participants
Start Date	2026-04-24
Primary Completion	2027-02-15 (estimated)
Study Completion	2027-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-23